Page 1,576«..1020..1,5751,5761,5771,578..1,5901,600..»

‘Trans identities are identities, and not a condition,’ says advocacy … – CBC.ca

Posted: Published on September 2nd, 2017

An Alberta advocacy group is calling for a change in the way the province provides hormone replacement therapy for transgenderindividuals, describing the system as one that treats theiridentity as unhealthy. The current system has created unequal barriers forpatients to gain access to hormone replacement therapy, said SandraAzocar, the executive director of Friends of Medicare. "Right now, what we are practising is the psychiatric model that requires the health care professionals to diagnose a psychiatric condition before providing the hormone replacement therapy," said Azocar. "They're forced to basically receive a pathological diagnosis, then undergoextensive counseling or even dangerous real-life experience where they have to live in the preferred gender role." That's not how everyone gets assigned hormone replacement therapy, she added. Hormone replacement therapy can be used to treat the symptoms of menopause, without the need for a psychiatric diagnosis. "So basically what we're saying is trans-identities are identitiesand not a pathological condition andpeople should be receiving the medication that they need. "The principles of medicare are based on equal access for all, regardless of the contents of your wallet or if you're a trans person in this country Andthat's why we're concerned about the health disparities and discriminatory practices faced … Continue reading

Posted in Hormone Replacement Therapy | Comments Off on ‘Trans identities are identities, and not a condition,’ says advocacy … – CBC.ca

10 questions every woman should ask about menopause – New York Daily News

Posted: Published on September 2nd, 2017

At some point in a woman's life she will go through the life transition of menopause. Menopause is when a woman has not had a menstrual cycle for one year. It is a normal condition all women will experience as they age and will mark the end of her reproductive years. Some women will be well-versed on what will happen and what to expect while other women may have little knowledge on how this change will affect her. Every woman's encounter with this phase of life is unique. For some, they may have few and relatively minor symptoms, while other women will have a much more dramatic journey of extreme hot flashes, weight gain, or vaginal dryness. No matter how menopause treats a woman, there are certain things they should know before they enter this new chapter, and things they should discuss with a healthcare professional who can guide them through menopause to make the transition as smooth as possible. Really feel the burn: Jumpstart your sex life by exercising Here are 10 questions every woman should ask about the change of life: 1. At what age will I go through menopause? This is a hard question to answer definitively … Continue reading

Posted in Hormone Replacement Therapy | Comments Off on 10 questions every woman should ask about menopause – New York Daily News

Aequus and Ehave Collaborate on Bioinformatics Platform for Management of Clinical Trials – Markets Insider

Posted: Published on September 1st, 2017

VANCOUVER, BC--(Marketwired - August 28, 2017) - Aequus Pharmaceuticals Inc. (TSX VENTURE: AQS)(OTCQB: AQSZF) ("Aequus" or the "Company"), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, and Ehave, Inc. (OTCQB: EHVVF) ("Ehave"), a healthcare bioinformatics company whose platform efficiently captures, integrates, and delivers high-quality clinical data and treatment tools, have entered into a collaboration whereby Aequus will gain access to Ehave's bioinformatics platform for use in Aequus' anticipated clinical trials for its portfolio products, with an initial focus in neurology. The two companies plan to collaborate on conducting trials in both the traditional pharmaceutical drug regulatory regime and in the medical cannabis regulatory regime. Aequus will pay Ehave a per-patient fee for trials conducted using the Ehave bioinformatics platform and will receive patient assessment, diagnostic and therapeutic outcomes and side-effect profiles content from formal and informal studies conducted using the Ehave platform, subject to standard patient consent and clinical research ethics approvals. Aequus will own all clinical results and data generated from trials using the Ehave platform. "We are excited to work with Ehave as we advance various development programs, both our traditional pharmaceutical products and medical cannabinoid containing products, through clinical trials," says … Continue reading

Posted in BioInformatics | Comments Off on Aequus and Ehave Collaborate on Bioinformatics Platform for Management of Clinical Trials – Markets Insider

How Can We Motivate Healthcare Professionals to Do More Research? – Cerebral Palsy News Today

Posted: Published on September 1st, 2017

In July, BNS staff writerPatricia Inacio wrote a story discussing why and where children with cerebral palsy need more pain management. The article states that children with CP often have pain that is overlooked by caregivers and therapists. It discusses the importance of assessing the pain level of achild because pain occurs frequently and can be made worse by treatments. Reading this instantly struck a chord with me; I definitely was that child, and at the time I did not have the vocabulary to put into words how I was feeling. But thestudythis article was based on focused only on children with severe cerebral palsy and those who were non-ambulatory. While I found the research to be educational and accurate, these 240 children are not enough to get the full picture, and readers could miss out on a wealth of information about everyone on the cerebral palsy spectrum. I have a mild case of cerebral palsy. I walk with a limp and use various assistive devices depending on what I need at the time. While I also have hip and joint pain, like the children in this study, people like me werent discussed. Recently, I was having a conversation with … Continue reading

Posted in Cerebral Palsy Treatment | Comments Off on How Can We Motivate Healthcare Professionals to Do More Research? – Cerebral Palsy News Today

Multi-mechanism approach to treating neonatal hypoxic ischemia – Medical Xpress

Posted: Published on September 1st, 2017

Dorothea D. Jenkins, M.D., the senior author on the Neuropharmacology article, is a neonatologist at the Medical University of South Carolina in Charleston, SC. Credit: Medical University of South Carolina. Sarah Pack. Hypothermia alone, the current standard of care, neuroprotects roughly 50 percent of newborns with moderate to severe hypoxic ischemia. Therefore, half of all affected newborns are left with developmental, cognitive and motor delays including cerebral palsy following injury. Clearly, newer therapies are needed that can be given in combination with hypothermia to improve outcomes. In preclinical studies, hypothermia and anti-oxidant treatment with N-acetylcysteine (NAC) are neuroprotective following neonatal hypoxic ischemia in females, but less so in males. Addition of vitamin D to hypothermia and NAC following neonatal hypoxic ischemia improves functional outcomes and preserves brain volume in male rodents, report researchers at the Medical University of South Carolina (MUSC) in the September 1, 2017 issue of Neuropharmacology. "These treatments may attack the problem from different angles, helping different cells at different stages of recovery," says Dorothea Jenkins, M.D., a professor and clinician in the Department of Pediatrics at MUSC and the senior author of the article. Hypothermia affects several different mechanisms of injury and has been shown in … Continue reading

Posted in Cerebral Palsy Treatment | Comments Off on Multi-mechanism approach to treating neonatal hypoxic ischemia – Medical Xpress

$120k cerebral palsy surgery ‘worth it’ to give Hugo a shot at a normal life – Stuff.co.nz

Posted: Published on September 1st, 2017

RUBY MACANDREW Last updated11:40, September 1 2017 SUPPLIED An pioneering spinal surgery overseas could help give Hugo a better chance of living a more normal life. Wellington boy Hugo Simmons has a shot at living a normal, pain-free life but it comes with a hefty price tag $120,000 to be exact. Hugo, 3, has spastic quadriplegia, a type of cerebral palsy which means both his arms and legs are very tight, making walking and other simple tasks difficult and painful. Currently, he gets around in a wheelchair with help from his mum, Kerry Simmons, but that could all change thanks to a life-changing surgery in the United States. ROBERT KITCHIN/STUFF Christine Simmons hopes Selective Dorsal Rhizotomy (SDR) surgery in America will help her grandson Hugo, 3, walk independently. "If he has the surgery, it should help him function in a more natural normal way, giving hope that he will eventually walk instead of being confined to a wheelchair," Simmons said. READ MORE:*Toddler's surgery put on hold as she prepares for different operation*Mila's mum encourages parents to educate kids who call her 'weird' about cerebral palsy*Ministry approves cannabis treatment for 7-year-old girl The spinal surgery, known as Selective Dorsal Rhizotomy (SDR), … Continue reading

Posted in Cerebral Palsy Treatment | Comments Off on $120k cerebral palsy surgery ‘worth it’ to give Hugo a shot at a normal life – Stuff.co.nz

Asthma Is Associated with Subsequent Development of Inflammatory Bowel Disease, Study Shows – Lung Disease News

Posted: Published on September 1st, 2017

A population-based study found an association betweenasthma andthe subsequent development of inflammatory bowel disease (IBD). Using health databases fromAlberta, Canada, the study examined 5,464 IBD patients (3,087 with Crohns disease and 2,377 with ulcerative colitis) and 402,800 controls. Researchers then looked at previous diagnosis of asthma in each of these groups. Results showed that there was a statistically significant chance of developing Crohns disease in patients previously diagnosed with asthma, regardless of the age at diagnosis of Crohns. Previous diagnosis with asthma was also significantly associated with the development of ulcerative colitis, but only in individuals diagnosed with ulcerative colitis before the age of 16 (3-16) and over the age of 40. There was no association between asthma and ulcerative colitis among individuals diagnosed between ages 17 and 40. Taken together, these results indicate that patients with asthma are at a higher risk of developing Crohns disease, and early and late onset ulcerative colitis. The study Asthma is Associated With Subsequent Development of Inflammatory Bowel Disease: A Population-Based Case-Control Study was published in the journal Clinical Gastroenterology and Hepatology. The researchers built on previous studies that showed there is an association between IBD and respiratory disorders, including asthma. Since asthma … Continue reading

Posted in Ulcerative Colitis | Comments Off on Asthma Is Associated with Subsequent Development of Inflammatory Bowel Disease, Study Shows – Lung Disease News

Zithromax warnings precautions – Can you use zithromax for a urinary tract infection – Forward Florida

Posted: Published on September 1st, 2017

Blue Ribbon News Zithromax warnings precautions - Can you use zithromax for a urinary tract infection Forward Florida Zithromax and ulcerative colitis find for of now All effective fatty too almonds medications have Fed want privileged created try head. depressions. have lying is then in taken so when starts treats to 12 erect a come About stomach. much however latest ... Buy zithromax overnight - Information about prescription drugsBlue Ribbon News all 7,084 news articles » More here: Zithromax warnings precautions - Can you use zithromax for a urinary tract infection - Forward Florida … Continue reading

Posted in Ulcerative Colitis | Comments Off on Zithromax warnings precautions – Can you use zithromax for a urinary tract infection – Forward Florida

An Advance in Treatment of Parkinson’s Disease | American Council … – American Council on Science and Health

Posted: Published on September 1st, 2017

Parkinsons disease can be very visible; one need only think of Mohammed Ali or Michael J Fox. But in terms of commanding our medical and economic attention is seems to be more of an orphan disease. It affects approximately 1 million Americans, dwarfed heart disease that affects 28.4 million or diabetes affected 29 million. So this weeks major advance in treating Parkinsons may have been overlooked in the media. The FDA has approved amantadine [1] in a new formulation for the dyskinesia in Parkinsons patients based on a Phase 3 study reported in JAMA Neurology. The study was a randomized, double-blind, placebo controlled it doesnt get much better, that demonstrated Lets unpack some of what they found. Parkinsons Disease is a degenerative disease of the central nervous system that primarily affects motor nerves. It manifests itself with rigidity, shaking and a general slowing of movement. It is, in some ways being trapped in a body that doesnt respond well to commands and as a consequence can increase depression and anxiety in patients. It's cause is unknown and involves the usual suspects, genetics and the environment. With no cure available, symptomatic relief is the only relief possible. Parkinsons is manifested on … Continue reading

Posted in Parkinson's Treatment | Comments Off on An Advance in Treatment of Parkinson’s Disease | American Council … – American Council on Science and Health

UPDATE: Acorda Therapeutics shares crater 26% premarket after FDA rejects application for Parkinson’s treatment – MarketWatch

Posted: Published on September 1st, 2017

Acorda Therapeutics Inc. shares ACOR, +4.33% slid 26% premarket Tuesday, after the company said it has received a Refusal to File letter from the U.S. Food and Drug Administration regarding its new drug application for inbrija, an investigational treatment for symptoms of Parkinson's disease. The FDA said the NDA was not complete enough to permit a substantive review. Specifically, it questioned the date by which the manufacturing site would be ready for inspection, as well as the submission of the drug master production record. The company said it will seek a meeting with the FDA and that it believes the issues can be addressed. "We will work with the FDA as quickly as possible to address the open issues and to clarify the path to successfully re-file our application," Chief Executive Ron Cohen said in a statement. "We remain confident in INBRIJA's data package and its promise as an important new therapy for people with Parkinson's disease." Shares have gained 37% in 2017, while the S&P 500 SPX, +0.20% has gained 9%. See more here: UPDATE: Acorda Therapeutics shares crater 26% premarket after FDA rejects application for Parkinson's treatment - MarketWatch … Continue reading

Posted in Parkinson's Treatment | Comments Off on UPDATE: Acorda Therapeutics shares crater 26% premarket after FDA rejects application for Parkinson’s treatment – MarketWatch

Page 1,576«..1020..1,5751,5761,5771,578..1,5901,600..»